Conduit Pharmaceuticals Inc. (CDT) Income Statement
CDT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCDT revenue and net income
Where CDT's revenue goes
2025Each bar shows an amount and its share of revenue. CDT kept −1.4% of revenue as net income.
CDT profit margins
CDT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +194.4% | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CDT quarterly EPS vs estimates
Next report: November 12, 2026.
CDT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.72B | $922.2M | $0 | $0 | $0 |
| Cost of revenue | $1.68B | $457,000 | — | — | — |
| Gross profit | $1.03B | −$457,000 | — | — | — |
| Research & development | $5.1M | $3.4M | $90,000 | $111,000 | $283,000 |
| Sales, general & admin | $31.7M | $12.0M | $5.2M | $3.0M | $2.9M |
| Total operating expenses | $36.8M | $15.4M | $5.3M | $3.2M | $3.2M |
| Operating income | −$36.8M | −$15.4M | −$5.3M | −$3.2M | −$3.2M |
| Interest income | $28,000 | $13,000 | $30,000 | $0 | — |
| Interest expense | $319,000 | $1.5M | $211,000 | $0 | — |
| Income before taxes | −$39.2M | −$17.8M | $2.8M | −$4.9M | −$3.7M |
| Income taxes | $29.3M | −$29.5M | −$168,000 | $374,862 | $247,442 |
| Net income | −$39.2M | −$17.8M | −$535,000 | −$4.9M | −$3.7M |
| EBITDA | −$36.5M | −$15.8M | $3.1M | −$4.9M | −$3.7M |
| EPS (diluted) | −$57880.26 | −$3000002.15 | −$1230218.76 | $0.01 | — |
| Gross margin | 38.0% | −0.0% | — | — | — |
| Operating margin | −1.4% | −1.7% | — | — | — |
| Net margin | −1.4% | −1.9% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $750.2M | $696.4M | $2.72B | $698.2M | $672.0M | $624.9M | $1.08B | $654.9M | $0 | $535.7M | $0 | $0 |
| Cost of revenue | $449.1M | $438.3M | $515,000 | $885,000 | $828,000 | $190,000 | $452,000 | $5,000 | $377.5M | $334.1M | — | — |
| Gross profit | $301.0M | $258.1M | −$515,000 | −$885,000 | −$828,000 | −$190,000 | −$452,000 | −$5,000 | −$695.9M | $201.6M | — | — |
| Research & development | $32.9M | $30.1M | $746,000 | $1.5M | $1.9M | $916,000 | $132,000 | $3.1M | $25,000 | $128,000 | $90,000 | $0 |
| Sales, general & admin | $2.7M | $138.7M | $20.4M | $5.5M | $3.1M | $2.7M | $3.4M | $2.7M | $3.1M | $2.8M | $805,000 | $430,000 |
| Total operating expenses | $183.7M | $180.1M | $21.2M | $7.0M | $5.0M | $3.6M | $3.5M | $5.8M | $3.1M | $3.0M | $895,000 | $430,000 |
| Operating income | $117.4M | $78.0M | −$21.2M | −$7.0M | −$5.0M | −$3.6M | −$3.5M | −$5.8M | −$3.1M | −$3.0M | −$895,000 | −$430,000 |
| Interest income | $0 | $0 | $9,000 | $7,000 | $4,000 | $8,000 | $2,000 | $8,000 | $2,000 | $9,000 | — | $0 |
| Interest expense | $40.5M | $13.5M | $38,000 | $48,000 | $57,000 | $176,000 | $960,000 | $310,000 | $119,000 | $119,000 | $330,000 | $47,000 |
| Income before taxes | $85.2M | $62.8M | −$21.3M | −$7.1M | −$6.0M | −$4.8M | −$2.4M | −$6.5M | −$5.4M | −$3.6M | $1.8M | $2.6M |
| Income taxes | $16.7M | $11.7M | $29.4M | −$97,000 | −$5.7M | −$10.1M | $10,000 | −$60.2M | −$11.1M | −$8.4M | $300,000 | $47,000 |
| Net income | $68.5M | $51.0M | −$21.3M | −$7.1M | −$6.0M | −$4.8M | −$2.4M | −$6.5M | −$5.4M | −$3.6M | $1.8M | $2.6M |
| EBITDA | $127.7M | $108.7M | −$18.9M | −$6.2M | −$5.1M | −$4.4M | −$994,000 | −$6.1M | $18.3M | −$3.4M | $1.9M | $2.6M |
| EPS (diluted) | −$8.71 | −$99.99 | −$57860.32 | −$13.16 | −$5.46 | −$1.32 | −$2.15 | −$1000000.00 | −$1000000.00 | −$1000000.00 | −$1000000.00 | −$230218.76 |
| Gross margin | 40.1% | 37.1% | −0.0% | −0.1% | −0.1% | −0.0% | −0.0% | −0.0% | — | 37.6% | — | — |
| Operating margin | 15.6% | 11.2% | −0.8% | −1.0% | −0.7% | −0.6% | −0.3% | −0.9% | — | −0.6% | — | — |
| Net margin | 9.1% | 7.3% | −0.8% | −1.0% | −0.9% | −0.8% | −0.2% | −1.0% | — | −0.7% | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CDT's financial statements (latest annual report filed February 17, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CDT financial results
In fiscal year 2025 (ended December 31, 2025), Conduit Pharmaceuticals reported revenue of $2.7 billion, up 194.4% from the year before. It had a net loss of $39.2 million, a net profit margin of −1.4%. Diluted earnings per share came to −$57880.26.
See the CDT stock overview for the latest quote and news, or the CDT chart for price history and technical indicators.
CDT income statement FAQ
What is Conduit Pharmaceuticals's annual revenue?
Conduit Pharmaceuticals reported total revenue of $2.7 billion for fiscal year 2025, which ended on December 31, 2025. That was up 194.4% from $922.2 million the previous year.
Is Conduit Pharmaceuticals profitable?
No. Conduit Pharmaceuticals reported a net loss of $39.2 million in fiscal 2025, a net profit margin of −1.4%; its operating margin was −1.4%.
What is Conduit Pharmaceuticals's gross margin?
Conduit Pharmaceuticals's gross margin was 38.0% in fiscal 2025: for every $100 of revenue, Conduit Pharmaceuticals kept $38 after the direct cost of its products and services.
How much does Conduit Pharmaceuticals spend on research and development?
Conduit Pharmaceuticals spent $5.1 million on research and development in fiscal 2025, 0.2% of revenue.
What are Conduit Pharmaceuticals's earnings per share?
Conduit Pharmaceuticals earned $-57880.26 per diluted share in fiscal 2025, compared with $-3000002.15 a year earlier.
When will Conduit Pharmaceuticals report its next earnings?
Conduit Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Conduit Pharmaceuticals's fiscal year end?
Conduit Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 17, 2026.